Depemokimab significantly reduces asthma exacerbations, benefiting patients regardless of their baseline asthma control levels. A biologics license application for depemokimab is currently being ...

GSK, which also has phase 3 programmes running for depemokimab in EGPA and HES, has previously put a target peak sales figure of £3 billion ($3.9 billion) a year on the drug.

GSK stock is up 21.5% in six months, fueled by strong Specialty Medicines growth and a promising pipeline despite vaccine headwinds.

GSK's long-acting drug antibody for severe asthma, depemokimab, cut the rate of attacks by 54% in phase 3 trials presented at ERS.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Depemokimab targets interleukin-5 (IL-5), which plays a crucial role in type 2 inflammation. GSK’s submission is supported by the positive Phase III SWIFT and ANCHOR trial data.

Phase 1 and interim phase 2 data met GSK’s immunogenicity success criteria, the London-based drugmaker said. Yet, GSK has decided to hand off to India’s Bharat for the phase 3 trial.